Overall, these data support, as already observed for other predictive biomarkers in GCs, that, if possible, CLDN18 status should be assessed in multiple biopsies obtained from the primary tumor to overcome intratumor heterogeneity, and that 6 biopsies should be considered as a standard of sampling for an adequate immunohistochemical profiling. This evidence concerns the gene CLDN18 and neoplasm.